Lothar Müller
Praxis
40 Papers
89 Citations
Lothar Müller is an academic researcher from Praxis. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 8, co-authored 40 publications.
Chat about Author
Papers
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
Nadia Harbeck,Steffen Saupe,Elke Jäger,Marcus Schmidt,Rolf Kreienberg,Lothar Müller,Burkhard Otremba,Dirk Waldenmaier,Julia Dorn,Mathias Warm,Michael Scholz,Michael Untch,Maike de Wit,Jana Barinoff,Hans-Joachim Lück,Philipp Harter,Doris Augustin,Paul R. Harnett,Matthias W. Beckmann,Salah-Eddin Al-Batran +19 more
TL;DR: Both pegylated liposomal doxorubicin and capecitabine are effective first-line agents for MBC.
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).
Dominik Paul Modest,Dominik Paul Modest,Meinolf Karthaus,Stefan Fruehauf,Ullrich Graeven,Lothar Müller,Alexander König,Ludwig Fischer von Weikersthal,Karel Caca,Albrecht Kretzschmar,Eray Goekkurt,Siegfried Haas,Annika Kurreck,A. Stahler,Swantje Held,Armin Jarosch,David Horst,David Horst,Anke Reinacher-Schick,Stefan Kasper,Volker Heinemann,Volker Heinemann,Sebastian Stintzing,Sebastian Stintzing,Tanja Trarbach +24 more
TL;DR: The randomized PANAMA trial as discussed by the authors investigated the efficacy of panitumumab (Pmab) when added to maintenance therapy with fluorouracil and folinic acid (FU/FA) in patients with RAS wild-type metastasis.
42
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
Volkmar Müller,Malgorzata Banys-Paluchowski,Twp Friedl,Peter A. Fasching,Andreas Schneeweiss,Andreas D. Hartkopf,Diethelm Wallwiener,Brigitte Rack,Franziska Meier-Stiegen,Jens Huober,Matthias Rübner,Oliver Hoffmann,Lothar Müller,Wolfgang Janni,Pauline Wimberger,Bernadette Jäger,Klaus Pantel,Sabine Riethdorf,Nadia Harbeck,Tanja Fehm +19 more
- 25 Nov 2021
TL;DR: In this article, the authors used CELLSEARCH to detect circulating tumor cells (CTCs) in patients with HER2-negative metastatic breast cancer (MBC) and found that CTC status was significantly associated with overall survival (OS).
38
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
Manuela Hoechstetter,Raymonde Busch,Barbara Eichhorst,Andreas Bühler,Dirk Winkler,Jasmin Bahlo,Sandra Robrecht,Michael J. Eckart,Ursula Vehling-Kaiser,Georg Jacobs,Ulrich Jäger,Hans Jürgen Hurtz,Georg Hopfinger,Frank Hartmann,Harald Fuss,Wolfgang Abenhardt,Ilona Blau,Werner Freier,Lothar Müller,Maria Elisabeth Goebeler,Clemens M. Wendtner,Kirsten Fischer,Carmen D. Herling,Michael Starck,Martin Bentz,Bertold Emmerich,Hartmut Döhner,Stephan Stilgenbauer,Michael Hallek +28 more
TL;DR: The aim of the multicenter, prospective CLL1 trial was to explore a novel prognostic model developed to identify risk groups, separating patients with favorable from others with dismal prognosis, and substantiated del(11q) and LDT as prognostic factors in early CLL.
38
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
Christoph Thomssen,Diana Lüftner,Michael Untch,Renate Haidinger,Rachel Würstlein,Nadia Harbeck,Doris Augustin,Susanne Briest,Johannes Ettl,Peter A. Fasching,F Förster,Christian M. Kurbacher,Hans-Joachim Lück,Norbert Marschner,Lothar Müller,Volkmar Müller,Lidia Perlova-Griff,Isabel Radke,Eugen Ruckhäberle,Iris Scheffen,Eva Schumacher-Wulf,Moritz Schwoerer,Dieter Steinfeld-Birg,Katja Ziegler-Löhr +23 more
TL;DR: A working group of German breast cancer experts comments on the results of the on-site ABC5 consensus votes by ABC panelists regarding their applicability for routine treatment in Germany and takes the recommendations of the Breast Committee of the Gynecological Oncology Working Group into account.